The patient population was lacking molecularly defined subtypes which would allow for genotype specific therapy approaches—mainly as participants in competing trials—such as patients with mutated NPM1, AML with FLT3-ITD, PML-RARA fusion, and CBF-AML. Here, RARA is linked to acute myeloid leukemia.